satisfactory antibacterial activity in vivo,and its effect was similar to that of the approved drugretapamulin,
QUESTION: This article does clearly present data and analysis supporting the anti-bacterial capacity of compound 6j in comparison to retapamulin, but it doesn't answer the question: what are the pharmacokinetic properties of compound 6j and how do they compare to the established drug, retapamulin? This is such a critical question when discussing a compounds potential for drug development because while the anti-bacterial capacity may be great and cytotoxicity data compelling as well, if the absorbance, metabolism, distribution, and/or excretion of 6j is/are not good then it is not a viable option for anti-MRSA drug development for humans. However, data in that type of study may show that compound 6j in fact has a better overall pharmacokinetic profile in comparison to retapamulin, and this would lend greater support to the idea of using 6j for further drug development. That key question just hasn't been answered yet and so it's difficult to say whether this compound is actual a good reference for the development of anti-MRSA drugs.